Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $25.03, for a total value of $125,150.00. The sale was disclosed in a document filed with the SEC, which is available at this link.
Shares of EIDX stock traded down $0.62 on Friday, reaching $31.21. 152,750 shares of the company were exchanged, compared to its average volume of 129,883. The stock has a market capitalization of $1.15 billion and a PE ratio of -16.78. The company has a debt-to-equity ratio of 0.01, a current ratio of 19.04 and a quick ratio of 19.04. Eidos Therapeutics Inc has a one year low of $8.89 and a one year high of $32.96.
Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings results on Monday, April 15th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.01). On average, analysts anticipate that Eidos Therapeutics Inc will post -1.6 earnings per share for the current fiscal year.
A number of analysts have weighed in on EIDX shares. BMO Capital Markets initiated coverage on Eidos Therapeutics in a report on Friday, February 22nd. They set an “outperform” rating and a $28.00 price target for the company. JPMorgan Chase & Co. raised shares of Eidos Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 27th. Zacks Investment Research cut shares of Eidos Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. Finally, BTIG Research initiated coverage on shares of Eidos Therapeutics in a research report on Wednesday, April 17th. They set a “buy” rating and a $38.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Eidos Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $30.29.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: Recession
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.